Q: Would welcome your analysis on this small cap- it has recently received some positive reports. It appears to be cash flow positive and has a new drug approval.
5i Research Answer:
Medexus is small at $98M market cap, down 12% YTD. It has some revenue, and is targeting $100M in revenue from GRAFAPEX within five years after its launch. It historically has lost money but is expected to earn a small profit this year. It had about $14M net debt at year end and had cash flow (operating) of $16.7M for the year. There are risks here, and launches always cost money and do not always go as planned. But the company has shown it can develop products and go through the approval process. Insiders own 8% and there has been some buying. It looks decent for a higher risk sector position.